UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as |
|
| Industry | Pharmaceuticals; Biotech |
| Founded | 1988 |
| Headquarters | Tarrytown, New York, US (Headquarters) |
|
Area served
|
Worldwide |
|
Key people
|
|
| Revenue |  $4.1 billion |
|
Net income
|
$1.4 billion |
| Total assets | $5.6 billion |
| Owner | Sanofi (22.6%) |
| Website | www |
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
On March 26, 2012 Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. The new drug targets the PCSK9 gene.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810. REGN2810 was later named cemiplimab.
ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
EYLEA (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011. EYLEA developed to treat a common cause of blindness in the elderly.
ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.
PRALUENT (Alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by FDA on 24 July 2015
Trap Fusion Proteins: Regeneron’s novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-03 | 9.77 | 9.77 |
| Q1 2022 | 2022-05-04 | 11.49 | 11.49 |
| Q4 2021 | 2022-02-04 | 21.32 | 21.32 |
| Q3 2021 | 2021-11-04 | 14.33 | 14.33 |
| Q2 2021 | 2021-08-05 | 27.97 | 27.97 |
| Q1 2021 | 2021-05-06 | 10.09 | 10.09 |
| Q4 2020 | 2021-02-05 | 9.53 | 9.53 |
| Q3 2020 | 2020-11-05 | 8.36 | 8.36 |
| Q2 2020 | 2020-08-05 | 7.16 | 7.16 |
| 2016-07-12 | Reiterated Rating | BTIG Research | Hold | |
| 2016-07-11 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-30 | Reiterated Rating | Sanford C. Bernstein | Buy | |
| 2016-06-29 | Initiated Coverage | Sanford C. Bernstein | Outperform | $400.00 |
| 2016-06-23 | Reiterated Rating | Citigroup Inc. | Buy | $470.00 |
| 2016-06-17 | Reiterated Rating | Canaccord Genuity | Hold | $450.00 |
| 2016-06-08 | Downgrade | Chardan Capital | Sell | $325.00 |
| 2016-06-08 | Reiterated Rating | Wells Fargo | Hold | |
| 2016-06-08 | Reiterated Rating | Wells Fargo & Co. | Hold | |
| 2016-06-06 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-06-06 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-06-06 | Reiterated Rating | Piper Jaffray Cos. | Hold | |
| 2016-06-01 | Reiterated Rating | Leerink Swann | Outperform | $530.00 |
| 2016-05-23 | Reiterated Rating | Wells Fargo | Hold | |
| 2016-05-16 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-05-08 | Reiterated Rating | Leerink Swann | Buy | $523.00 to $530.00 |
| 2016-05-08 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-05-06 | Reiterated Rating | Canaccord Genuity | Hold | $450.00 |
| 2016-05-05 | Reiterated Rating | Robert W. Baird | Outperform | $526.00 to $505.00 |
| 2016-04-30 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-20 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2016-04-19 | Reiterated Rating | Jefferies Group | Hold | $444.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-04-12 | Reiterated Rating | Brean Capital | Buy | |
| 2016-04-09 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-08 | Lower Price Target | Morgan Stanley | $436.00 to $415.00 | |
| 2016-04-04 | Boost Price Target | Leerink Swann | Outperform | $505.00 to $523.00 |
| 2016-04-02 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-04-02 | Reiterated Rating | Roth Capital | Buy | $555.00 to $520.00 |
| 2016-04-02 | Reiterated Rating | Piper Jaffray | Hold | $443.00 |
| 2016-04-01 | Reiterated Rating | Credit Suisse | Hold | $481.00 |
| 2016-04-01 | Reiterated Rating | Credit Suisse Group AG | Hold | $481.00 |
| 2016-03-31 | Reiterated Rating | Canaccord Genuity | Hold | $525.00 to $450.00 |
| 2016-03-25 | Lower Price Target | Jefferies Group | Hold | $590.00 to $444.00 |
| 2016-03-25 | Reiterated Rating | Chardan Capital | Sell | $325.00 |
| 2016-03-24 | Reiterated Rating | Canaccord Genuity | Hold | $525.00 to $450.00 |
| 2016-03-24 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-03-19 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-03-18 | Reiterated Rating | Goldman Sachs | Buy | $506.00 |
| 2016-03-18 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | $506.00 |
| 2016-03-17 | Lower Price Target | SunTrust | Neutral | $450.00 to $410.00 |
| 2016-03-17 | Lower Price Target | SunTrust Banks Inc. | Neutral | $450.00 to $410.00 |
| 2016-03-16 | Downgrade | Chardan Capital | Neutral to Sell | $375.00 to $325.00 |
| 2016-03-15 | Initiated Coverage | Gabelli | Buy | $574.00 |
| 2016-03-15 | Reiterated Rating | Brean Capital | Buy | $489.00 |
| 2016-03-14 | Reiterated Rating | Jefferies Group | Hold | $444.00 |
| 2016-03-14 | Reiterated Rating | Canaccord Genuity | Hold | $525.00 |
| 2016-03-13 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2016-03-13 | Reiterated Rating | Piper Jaffray | Hold | $443.00 |
| 2016-03-08 | Initiated Coverage | Brean Capital | Buy | $489.00 |
| 2016-03-03 | Initiated Coverage | SunTrust | Neutral | $450.00 |
| 2016-03-01 | Reiterated Rating | Brean Capital | Buy | $489.00 |
| 2016-03-01 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $477.00 |
| 2016-02-29 | Reiterated Rating | Canaccord Genuity | Hold | $525.00 |
| 2016-02-25 | Initiated Coverage | Citigroup Inc. | Buy | $480.00 |
| 2016-02-22 | Lower Price Target | Goldman Sachs | $586.00 to $506.00 | |
| 2016-02-16 | Upgrade | Chardan Capital | Sell to Neutral | $400.00 to $375.00 |
| 2016-02-11 | Reiterated Rating | Bank of America | Buy | $649.00 to $525.00 |
| 2016-02-11 | Reiterated Rating | Bank of America Corp. | Buy | $649.00 to $525.00 |
| 2016-02-10 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $537.00 to $477.00 |
| 2016-02-10 | Reiterated Rating | Chardan Capital | Sell | $400.00 |
| 2016-02-10 | Lower Price Target | Morgan Stanley | Equal Weight | $583.00 to $436.00 |
| 2016-02-10 | Lower Price Target | Brean Capital | Buy | $659.00 to $489.00 |
| 2016-02-10 | Lower Price Target | Barclays | Equal Weight | $610.00 to $425.00 |
| 2016-02-10 | Reiterated Rating | Roth Capital | Buy | $555.00 |
| 2016-02-10 | Lower Price Target | Leerink Swann | Outperform | $534.00 to $505.00 |
| 2016-02-10 | Lower Price Target | Jefferies Group | $590.00 to $444.00 | |
| 2016-02-10 | Lower Price Target | Goldman Sachs | Buy | $597.00 to $586.00 |
| 2016-02-10 | Reiterated Rating | RBC Capital | Outperform | $676.00 to $668.00 |
| 2016-02-10 | Reiterated Rating | Royal Bank Of Canada | Outperform | $676.00 to $668.00 |
| 2016-02-10 | Lower Price Target | Barclays PLC | Equal Weight | $610.00 to $425.00 |
| 2016-02-09 | Lower Price Target | Piper Jaffray | Neutral | $607.00 to $443.00 |
| 2016-02-09 | Reiterated Rating | Robert W. Baird | Outperform | $674.00 to $525.00 |
| 2016-02-06 | Reiterated Rating | Leerink Swann | Buy | $534.00 to $505.00 |
| 2016-02-04 | Initiated Coverage | Leerink Swann | Outperform | $534.00 |
| 2016-02-01 | Reiterated Rating | Chardan Capital | Sell | $400.00 |
| 2016-01-27 | Downgrade | Canaccord Genuity | Buy to Hold | $700.00 to $525.00 |
| 2016-01-25 | Downgrade | Chardan Capital | Neutral to Sell | $525.00 to $400.00 |
| 2016-01-19 | Initiated Coverage | Credit Suisse | Neutral | $552.00 |
| 2016-01-19 | Upgrade | Roth Capital | Neutral to Buy | $543.00 to $555.00 |
| 2016-01-13 | Reiterated Rating | Canaccord Genuity | Buy | $700.00 |
| 2016-01-12 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2016-01-12 | Reiterated Rating | Cowen and Company | Market Perform | $575.00 |
| 2016-01-07 | Initiated Coverage | BTIG Research | Neutral | |
| 2015-12-03 | Initiated Coverage | Wells Fargo | Outperform | |
| 2015-11-13 | Reiterated Rating | Roth Capital | Hold | $543.00 |
| 2015-11-06 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $578.00 |
| 2015-11-05 | Boost Price Target | RBC Capital | Outperform | $665.00 to $676.00 |
| 2015-11-05 | Reiterated Rating | Leerink Swann | Buy | $664.00 |
| 2015-11-04 | Reiterated Rating | Cowen and Company | Hold | $550.00 to $575.00 |
| 2015-11-02 | Downgrade | Piper Jaffray | Outperform to Neutral | |
| 2015-11-02 | Boost Price Target | Morgan Stanley | Outperform | $489.00 to $499.00 |
| 2015-11-02 | Boost Price Target | Leerink Swann | $439.00 to $445.00 | |
| 2015-10-28 | Reiterated Rating | Roth Capital | Hold | $527.00 |
| 2015-10-26 | Reiterated Rating | Leerink Swann | Buy | $664.00 |
| 2015-10-04 | Reiterated Rating | Piper Jaffray | Hold | |
| 2015-10-02 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $593.00 |
| 2015-08-31 | Initiated Coverage | Raymond James | Outperform | $615.00 |
| 2015-08-31 | Reiterated Rating | RBC Capital | Buy | |
| 2015-08-31 | Downgrade | Chardan Capital | Buy to Neutral | $565.00 |
| 2015-08-31 | Initiated Coverage | Raymond James Financial Inc. | Outperform | $615.00 |
| 2015-08-24 | Reiterated Rating | RBC Capital | Buy | $565.00 |
| 2015-08-10 | Boost Price Target | Roth Capital | Neutral | $495.00 to $527.00 |
| 2015-08-06 | Boost Price Target | Argus | Buy | $560.00 to $660.00 |
| 2015-08-05 | Boost Price Target | Barclays | Equal Weight | $460.00 to $595.00 |
| 2015-08-05 | Reiterated Rating | Canaccord Genuity | Buy | $600.00 to $700.00 |
| 2015-08-05 | Reiterated Rating | Morgan Stanley | Buy | $520.00 to $593.00 |
| 2015-08-04 | Reiterated Rating | Sanford C. Bernstein | Outperform | |
| 2015-08-04 | Reiterated Rating | RBC Capital | Outperform | $570.00 to $665.00 |
| 2015-08-04 | Reiterated Rating | Brean Capital | Buy | $525.00 to $659.00 |
| 2015-08-04 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2015-08-04 | Reiterated Rating | Deutsche Bank | Buy | $650.00 to $720.00 |
| 2015-08-04 | Reiterated Rating | Piper Jaffray | Hold | $607.00 |
| 2015-08-04 | Reiterated Rating | Deutsche Bank AG | Buy | $650.00 to $720.00 |
| 2015-08-03 | Reiterated Rating | Chardan Capital | Buy | $565.00 |
| 2015-08-03 | Boost Price Target | Leerink Swann | Outperform | $559.00 to $630.00 |
| 2015-07-29 | Reiterated Rating | Canaccord Genuity | Buy | $600.00 to $700.00 |
| 2015-07-28 | Reiterated Rating | Deutsche Bank | Buy | $650.00 |
| 2015-07-28 | Reiterated Rating | Brean Capital | Buy | $525.00 to $659.00 |
| 2015-07-27 | Reiterated Rating | BMO Capital Markets | Market Perform | $381.00 to $494.00 |
| 2015-07-27 | Reiterated Rating | Roth Capital | Hold | $495.00 |
| 2015-07-27 | Boost Price Target | Jefferies Group | Hold | $442.00 to $502.00 |
| 2015-07-27 | Reiterated Rating | RBC Capital | Outperform | $560.00 to $570.00 |
| 2015-07-22 | Initiated Coverage | Northland Securities | Market Perform | $560.00 |
| 2015-07-21 | Reiterated Rating | Piper Jaffray | Hold | |
| 2015-07-20 | Boost Price Target | RBC Capital | Outperform | $550.00 to $560.00 |
| 2015-07-13 | Boost Price Target | Deutsche Bank | Buy | $455.00 to $650.00 |
| 2015-06-17 | Reiterated Rating | Piper Jaffray | Neutral | $484.00 |
| 2015-06-15 | Boost Price Target | RBC Capital | Outperform | $543.00 to $550.00 |
| 2015-06-12 | Reiterated Rating | Roth Capital | Neutral | $495.00 |
| 2015-06-10 | Set Price Target | Brean Capital | Buy | $525.00 |
| 2015-06-10 | Boost Price Target | Chardan Capital | Buy | $560.00 to $565.00 |
| 2015-06-08 | Reiterated Rating | Robert W. Baird | Outperform | $490.00 to $521.00 |
| 2015-06-08 | Reiterated Rating | BMO Capital Markets | Positive | $381.00 |
| 2015-06-06 | Reiterated Rating | RBC Capital | Outperform | $543.00 |
| 2015-05-21 | Reiterated Rating | Piper Jaffray | Neutral | $484.00 |
| 2015-05-20 | Reiterated Rating | Roth Capital | Neutral | $490.00 to $490.00 |
| 2015-05-20 | Boost Price Target | Canaccord Genuity | Buy | $525.00 to $600.00 |
| 2015-05-20 | Boost Price Target | Argus | Buy | $500.00 to $560.00 |
| 2015-05-19 | Boost Price Target | Brean Capital | Buy | $507.00 to $525.00 |
| 2015-05-15 | Set Price Target | Credit Suisse | Buy | $400.00 to $550.00 |
| 2015-05-15 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $427.00 to $450.00 |
| 2015-05-11 | Reiterated Rating | Citigroup Inc. | Buy | $474.00 to $537.00 |
| 2015-05-08 | Boost Price Target | Canaccord Genuity | Buy | $460.00 to $525.00 |
| 2015-05-08 | Boost Price Target | Brean Capital | Buy | $450.00 to $507.00 |
| 2015-05-07 | Set Price Target | Piper Jaffray | Hold | $415.00 to $484.00 |
| 2015-05-07 | Boost Price Target | Roth Capital | Neutral | $461.00 to $490.00 |
| 2015-05-07 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-05-06 | Boost Price Target | Leerink Swann | Outperform | $527.00 to $559.00 |
| 2015-05-05 | Reiterated Rating | Credit Suisse | Outperform | $400.00 |
| 2015-04-30 | Reiterated Rating | Canaccord Genuity | Buy | $460.00 |
| 2015-04-29 | Boost Price Target | RBC Capital | Outperform | $490.00 to $533.00 |
| 2015-04-24 | Boost Price Target | Leerink Swann | Buy | $445.00 to $527.00 |
| 2015-03-27 | Boost Price Target | Argus | Buy | $450.00 to $500.00 |
| 2015-03-23 | Initiated Coverage | Chardan Capital | Buy | $560.00 |
| 2015-03-18 | Reiterated Rating | Brean Capital | Buy | $450.00 |
| 2015-03-09 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $411.00 |
| 2015-02-19 | Set Price Target | Piper Jaffray | Hold | $416.00 |
| 2015-02-17 | Boost Price Target | Argus | Buy | $430.00 to $450.00 |
| 2015-02-11 | Set Price Target | Brean Capital | Buy | $450.00 |
| 2015-02-10 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2015-02-10 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2015-02-10 | Downgrade | Piper Jaffray | Overweight to Neutral | $399.50 to $416.00 |
| 2015-01-14 | Set Price Target | Brean Capital | Buy | $450.00 |
| 2015-01-09 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-01-06 | Initiated Coverage | Barclays | Equal Weight | $450.00 |
| 2015-01-05 | Set Price Target | JPMorgan Chase & Co. | Hold | $402.00 |
| 2014-11-20 | Boost Price Target | Brean Capital | Buy | $390.00 to $450.00 |
| 2014-11-11 | Boost Price Target | Argus | Buy | $375.00 to $430.00 |
| 2014-11-05 | Boost Price Target | RBC Capital | Outperform | $373.00 to $410.00 |
| 2014-10-17 | Reiterated Rating | Roth Capital | Positive | |
| 2014-10-02 | Initiated Coverage | Guggenheim | Buy | $432.00 |
| 2014-10-01 | Initiated Coverage | Bank of America | Buy | $420.00 |
| 2014-09-18 | Reiterated Rating | Morgan Stanley | Equal Weight | $310.00 |
| 2014-09-03 | Boost Price Target | Roth Capital | $399.00 to $422.00 | |
| 2014-09-02 | Boost Price Target | Brean Capital | Buy | $380.00 to $390.00 |
| 2014-09-02 | Reiterated Rating | Morgan Stanley | Equal Weight | $310.00 |
| 2014-09-02 | Boost Price Target | Credit Suisse | Outperform | $340.00 to $400.00 |
| 2014-09-02 | Boost Price Target | Leerink Swann | Outperform | $389.00 to $436.00 |
| 2014-08-06 | Boost Price Target | RBC Capital | Outperform | $349.00 to $373.00 |
| 2014-08-05 | Reiterated Rating | Roth Capital | Buy | |
| 2014-08-05 | Boost Price Target | Deutsche Bank | Buy | $410.00 to $425.00 |
| 2014-07-30 | Boost Price Target | Roth Capital | $382.00 to $399.00 | |
| 2014-07-21 | Initiated Coverage | Argus | Buy | $375.00 |
| 2014-07-18 | Reiterated Rating | Roth Capital | Buy | |
| 2014-07-10 | Reiterated Rating | Morgan Stanley | Equal Weight to Positive | $310.00 |
| 2014-06-24 | Reiterated Rating | Goldman Sachs | Buy | |
| 2014-05-09 | Lower Price Target | BMO Capital Markets | $331.00 to $283.00 | |
| 2014-05-09 | Boost Price Target | Cowen and Company | Market Perform | $276.00 to $285.00 |
| 2014-05-05 | Boost Price Target | Robert W. Baird | $362.00 to $368.00 | |
| 2014-04-21 | Upgrade | Ned Davis Research | Sell to Neutral | |
| 2014-04-16 | Initiated Coverage | Canaccord Genuity | Buy | $350.00 |
| 2014-03-31 | Boost Price Target | Roth Capital | $382.00 | |
| 2014-03-26 | Initiated Coverage | Morgan Stanley | Equal Weight | $320.00 |
| 2014-03-17 | Upgrade | Citigroup Inc. | Neutral to Buy | $342.00 to $390.00 |
| 2014-02-13 | Downgrade | Oppenheimer | Outperform to Market Perform | $310.00 to $325.00 |
| 2014-02-13 | Boost Price Target | RBC Capital | $344.00 to $348.00 | |
| 2014-02-13 | Boost Price Target | Goldman Sachs | Outperform to Market Perform | $353.00 to $383.00 |
| 2014-02-12 | Initiated Coverage | Bank of America | Buy | $387.00 |
| 2014-02-11 | Boost Price Target | Deutsche Bank | $410.00 | |
| 2014-01-15 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $331.00 |
| 2014-01-10 | Reiterated Rating | Barclays | Overweight | $340.00 |
| 2013-12-20 | Boost Price Target | RBC Capital | Outperform | $323.00 to $344.00 |
| 2013-11-27 | Initiated Coverage | Piper Jaffray | Overweight | $376.00 |
| 2013-11-06 | Boost Price Target | Jefferies Group | Hold | $251.00 to $274.00 |
| 2013-11-06 | Boost Price Target | Credit Suisse | Outperform | $275.00 to $340.00 |
| 2013-11-06 | Boost Price Target | Cowen and Company | Market Perform | $216.00 to $225.00 |
| 2013-11-06 | Boost Price Target | BMO Capital Markets | Outperform | $325.00 to $331.00 |
| 2013-11-06 | Reiterated Rating | Goldman Sachs | Buy | |
| 2013-11-05 | Boost Price Target | Leerink Swann | Outperform | $310.00 to $355.00 |
| 2013-11-05 | Boost Price Target | Deutsche Bank | $375.00 | |
| 2013-10-16 | Boost Price Target | Roth Capital | $319.00 to $345.00 | |
| 2013-10-16 | Reiterated Rating | Brean Capital | Buy | |
| 2013-10-10 | Boost Price Target | Barclays | Overweight | $305.00 to $339.00 |
| 2013-10-02 | Boost Price Target | Brean Capital | Buy | $315.00 to $367.00 |
| 2013-10-01 | Boost Price Target | Bank of America | Buy | $345.00 |
| 2013-09-30 | Reiterated Rating | Goldman Sachs | Buy | $329.00 to $355.00 |
| 2013-09-30 | Reiterated Rating | Piper Jaffray | Overweight | $336.00 to $360.00 |
| 2013-09-30 | Boost Price Target | Oppenheimer | Outperform | $300.00 to $310.00 |
| 2013-09-24 | Reiterated Rating | BMO Capital Markets | Buy | $294.00 to $325.00 |
| 2013-09-18 | Boost Price Target | Goldman Sachs | $298.00 to $329.00 | |
| 2012-02-14 | Reiterated | RBC Capital Mkts | Outperform | $83 to $130 |
| 2011-12-05 | Reiterated | Brean Murray | Buy | $78 to $67 |
| 2011-05-09 | Reiterated | Needham | Buy | $49 to $60 |
| 2016-07-12 | Reiterated Rating | BTIG Research | Hold | |
| 2016-07-11 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-30 | Reiterated Rating | Sanford C. Bernstein | Buy | |
| 2016-06-29 | Initiated Coverage | Sanford C. Bernstein | Outperform | $400.00 |
| 2016-06-23 | Reiterated Rating | Citigroup Inc. | Buy | $470.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In REGN 666 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| FMR LLC | 10.81M |
| BlackRock Inc. | 9.49M |
| Vanguard Group, Inc | 8.65M |
| Capital World Investors | 6.23M |
| JPMORGAN CHASE & CO | 5.71M |
| STATE STREET CORP | 5.05M |
| BlackRock Fund Advisors | 2.45M |
| WELLINGTON MANAGEMENT CO LLP | 2.44M |
| DODGE & COX | 2.29M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.24M |
| BlackRock Institutional Trust Company, N.A. | 2.04M |
| Capital International Investors | 1.77M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.75M |
| LOOMIS SAYLES & CO L P | 1.72M |
| JANUS CAPITAL MANAGEMENT LLC | 1.32M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SANOFI-AVENTIS | 23.86% (23641744) | ALNY / KBIO / REGN / RGLS / |
| REGENERON PHARMACEUTICALS INC | 1.83% (1809098) | AAVL / REGN / |
| YANCOPOULOS GEORGE Pres Regeneron Labs | 0.43% (422762) | REGN / |
| SCHLEIFER LEONARD S President & CEO | 0.27% (271593) | REGN / |
| VAGELOS P ROY Chairman of the Board | 0.15% (149717) | REGN / |
| SING GEORGE L | 0.14% (134772) | REGN / |
| GOLDBERG MURRAY A SVP Administration & Asst Secr | 0.07% (64436) | AERI / REGN / |
| RYAN ARTHUR F | 0.04% (39500) | CFG / JTPY / REGN / |
| STAHL NEIL SVP Research and Development S | 0.02% (23950) | REGN / |
| Terifay Robert J SVP Commercial | 0.02% (23293) | REGN / |
| LAROSA JOSEPH J SVP General Counsel and Secret | 0.02% (16756) | REGN / |
| GOLDSTEIN JOSEPH L | 0.01% (12000) | REGN / |
| BAKER CHARLES A | 0.01% (11000) | PGNX / REGN / |
| GILMAN ALFRED G | 0.01% (8912) | LLY / REGN / |
| Landry Robert E SVP Finance & CFO | 0.01% (7099) | REGN / |
| McCorkle Douglas S VP Controller and Asst Treasur | 0.01% (6866) | REGN / |
| Tessier-Lavigne Marc | 0.01% (6187) | AGIO / PFE / REGN / |
UM